ENA Respiratory Appoints Melissa Faris to Board

Melbourne, Australia, 23 April 2026 – ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence enhancers to minimize the impact of symptomatic viral respiratory infections, today announces the appointment of Melissa Faris as an independent Non-Executive Director.

Melissa is Chief Business Officer of OMass Therapeutics, a leading UK-based private biotechnology company, and was previously Vice President and Head of Immunology Business Development at GSK where she led a team responsible for end-to-end business development activities for immunology and infectious diseases.

In her twenty-year career at GSK, Melissa held a number of roles in respiratory medicines including Clinical Development Director, Respiratory Medicines and Head of Respiratory Business Development. She has contributed to development programs for respiratory medicines from Phase 1 through to registration and launch.

In addition to her roles at OMass and ENA, she serves on the Business Development Advisory Board of Sunstone Life Science Ventures and was previously a Non-Executive Board member for Sitryx Therapeutics.

Melissa Faris, Non-Executive Director of ENA Respiratory said, “I am truly excited to be joining the Board of ENA Respiratory. I have followed the company’s progress for a number of years and believe its innovative approach to reducing the often-devastating impacts of viral respiratory infections could offer a new option for millions of vulnerable patients worldwide.”

ENA Respiratory’s CEO, Christophe Demaison, PhD said: “We are proud to appoint Melissa to our Board. The depth and breadth of her pharmaceutical and biotechnology industry experience is exceptional and her international contacts and perspective, and relevant expertise in the respiratory and immunology space can only benefit ENA Respiratory as we continue to advance the clinical development of INNA-051.”